PRESTO: A Phase 3, Open-Label Study of Androgen Annihilation in Patients with High-Risk, Biochemically Relapsed Prostate Cancer (AFT-19)
   Google Scholar   
Citation:
Ann Oncol vol 33 (57) abstr LBA63
Meeting Instance:
ESMO 2022
Year:
2022
Type:
Abstract
Sub type:
Funding:
AFT
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
GU
Sec. Committees:
   
Pharmas:
Janssen  
Grants:
 
Corr. Author:
 
Authors:
                                         
Networks:
ADM400, ADM403, ALLIANCE, CA043, CA136, IL018, IL043, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NY016, LAPS-NY158, LAPS-PA015, LAPS-TX035, METROMIN, MN022, NEWMEXICO, NH038, NY018, NY361, TX041   
Study
AFT-19
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: